SCHEMBL2695480

SCHEMBL2695480

O=C(CCC(=O)N1CCC2(CCN(C3CCCCC3)CC2)C1)N1CCC(N(Cc2ncc[nH]2)Cc2ncc[nH]2)CC1

nearest known ligand 0.36

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CXCR4 P61073 2/20 0.36
HRH3 Q9Y5N1 8/20 0.36
OPRM1 P35372 1/20 0.36
OPRL1 P41146 1/20 0.36
ALDH1A1 P00352 2/20 0.35
KMT2A Q03164 2/20 0.35
MEN1 O00255 1/20 0.35
ITGB3 P05106 1/20 0.35
ITGA2B P08514 1/20 0.35
PDE3B Q13370 2/20 0.35
PDE3A Q14432 2/20 0.35
L3MBTL3 Q96JM7 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
POLB P06746 1/20 0.34
TSHR P16473 1/20 0.33
LRRK2 Q5S007 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2694422 0.94 ITGB3 (0.36) CXCR4HRH3OPRM1OPRL1ALDH1A1
SCHEMBL2692831 0.92 CXCR4 (0.36) CXCR4HRH3OPRM1OPRL1ALDH1A1
SCHEMBL2695440 0.90 CXCR4 (0.34) CXCR4HRH3OPRM1OPRL1ALDH1A1
SCHEMBL2695053 0.90 CXCR4 (0.37) CXCR4HRH3OPRM1OPRL1ALDH1A1
SCHEMBL14102781 0.87 CXCR4 (0.33) CXCR4HRH3OPRM1OPRL1ALDH1A1
SCHEMBL2693776 0.86 HRH3 (0.45) CXCR4HRH3ALDH1A1KMT2AMEN1
SCHEMBL2693076 0.83 CXCR4 (0.36) CXCR4HRH3OPRM1OPRL1ALDH1A1
SCHEMBL2692227 0.80 HSD11B1 (0.45) CXCR4HRH3OPRM1OPRL1ALDH1A1
SCHEMBL2694751 0.79 CXCR4 (0.36) CXCR4HRH3OPRM1OPRL1ALDH1A1
SCHEMBL2693941 0.78 CXCR4 (0.41) CXCR4HRH3OPRM1OPRL1ITGB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1961744-B1 BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF ONO PHARMACEUTICAL CO (JP) 2013-04-17 EP claimed
US-8519124-B2 Chemokine receptor antagonists and use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2013-08-27 US disclosed
EP-1961744-B1 BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF ONO PHARMACEUTICAL CO (JP) 2013-04-17 EP disclosed
US-20120207765-A1 CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2012-08-16 US disclosed
US-8168783-B2 Chemokine receptor antagonists and use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2012-05-01 US disclosed
US-20090169567-A1 BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF ONO PHARMACEUTICAL CO., LTD., (JP) 2009-07-02 US disclosed
EP-1961744-A1 BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2008-08-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090169567-A1 BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF CXCR4, CXCL12, CXCR3 CXCR4 1/4885HRH3 513/4885OPRM1 1016/4885
US-20120207765-A1 CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF CXCR4, CXCR3, CXCR1 CXCR4 1/4885HRH3 548/4885OPRM1 841/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.